Deamination Hotspots Among APOBEC3 Family Members Are Defined by Both Target Site Sequence Context and SsDNA Secondary Structure

Overview

Journal Nucleic Acids Res

Publisher Oxford University Press

Specialty Biochemistry

Date 2020 Jan 17

PMID 31943071

Citations 30

Authors

Yumeng Z McDaniel

Dake Wang

Robin P Love

Madison B Adolph

Nazanin Mohammadzadeh

Linda Chelico

Louis M Mansky

Affiliations

Soon will be listed here.

Abstract

The human apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3 (APOBEC3, A3) family member proteins can deaminate cytosines in single-strand (ss) DNA, which restricts human immunodeficiency virus type 1 (HIV-1), retrotransposons, and other viruses such as hepatitis B virus, but can cause a mutator phenotype in many cancers. While structural information exists for several A3 proteins, the precise details regarding deamination target selection are not fully understood. Here, we report the first parallel, comparative analysis of site selection of A3 deamination using six of the seven purified A3 member enzymes, oligonucleotides having 5'TC3' or 5'CT3' dinucleotide target sites, and different flanking bases within diverse DNA secondary structures. A3A, A3F and A3H were observed to have strong preferences toward the TC target flanked by A or T, while all examined A3 proteins did not show a preference for a TC target flanked by a G. We observed that the TC target was strongly preferred in ssDNA regions rather than dsDNA, loop or bulge regions, with flanking bases influencing the degree of preference. CT was also shown to be a potential deamination target. Taken together, our observations provide new insights into A3 enzyme target site selection and how A3 mutagenesis impacts mutation rates.

Citing Articles

UVA-light-induced mutagenesis in the exome of human nucleotide excision repair-deficient cells.

Quintero-Ruiz N, Corradi C, Moreno N, de Souza T, Menck C Photochem Photobiol Sci. 2025; .

PMID: 40063310 DOI: 10.1007/s43630-025-00697-9.

Leong S, Nasser H, Ikeda T Int J Mol Sci. 2025; 26(4).

PMID: 40004025 PMC: 11855278. DOI: 10.3390/ijms26041561.

Molecular mechanism for regulating APOBEC3G DNA editing function by the non-catalytic domain.

Yang H, Pacheco J, Kim K, Bokani A, Ito F, Ebrahimi D Nat Commun. 2024; 15(1):8773.

PMID: 39389938 PMC: 11467180. DOI: 10.1038/s41467-024-52671-1.

Molecular mechanism for regulating APOBEC3G DNA editing function by the non-catalytic domain.

Yang H, Pacheco J, Kim K, Ebrahimi D, Ito F, Chen X bioRxiv. 2024; .

PMID: 38559028 PMC: 10980023. DOI: 10.1101/2024.03.11.584510.

Expanded palette of RNA base editors for comprehensive RBP-RNA interactome studies.

Medina-Munoz H, Kofman E, Jagannatha P, Boyle E, Yu T, Jones K Nat Commun. 2024; 15(1):875.

PMID: 38287010 PMC: 10825223. DOI: 10.1038/s41467-024-45009-4.

References

Peliska J, Benkovic S . Mechanism of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase. Science. 1992; 258(5085):1112-8. DOI: 10.1126/science.1279806. View

Beale R, Petersen-Mahrt S, Watt I, Harris R, Rada C, Neuberger M . Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol. 2004; 337(3):585-96. DOI: 10.1016/j.jmb.2004.01.046. View

Holtz C, Sadler H, Mansky L . APOBEC3G cytosine deamination hotspots are defined by both sequence context and single-stranded DNA secondary structure. Nucleic Acids Res. 2013; 41(12):6139-48. PMC: 3695494. DOI: 10.1093/nar/gkt246. View

Harris R, Liddament M . Retroviral restriction by APOBEC proteins. Nat Rev Immunol. 2004; 4(11):868-77. DOI: 10.1038/nri1489. View

King J, Larijani M . A Novel Regulator of Activation-Induced Cytidine Deaminase/APOBECs in Immunity and Cancer: Schrödinger's CATalytic Pocket. Front Immunol. 2017; 8:351. PMC: 5382155. DOI: 10.3389/fimmu.2017.00351. View

Xiao X, Li S, Yang H, Chen X . Crystal structures of APOBEC3G N-domain alone and its complex with DNA. Nat Commun. 2016; 7:12193. PMC: 4974639. DOI: 10.1038/ncomms12193. View

Maiti A, Myint W, Kanai T, Delviks-Frankenberry K, Sierra Rodriguez C, Pathak V . Crystal structure of the catalytic domain of HIV-1 restriction factor APOBEC3G in complex with ssDNA. Nat Commun. 2018; 9(1):2460. PMC: 6018426. DOI: 10.1038/s41467-018-04872-8. View

Anderson J, Hope T . APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells. Virology. 2008; 375(1):1-12. PMC: 2679893. DOI: 10.1016/j.virol.2008.01.042. View

von Hippel P, Johnson N, Marcus A . Fifty years of DNA "breathing": Reflections on old and new approaches. Biopolymers. 2013; 99(12):923-54. PMC: 4313903. DOI: 10.1002/bip.22347. View

10.

Dyda F, Hickman A, Jenkins T, Engelman A, Craigie R, Davies D . Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science. 1994; 266(5193):1981-6. DOI: 10.1126/science.7801124. View

11.

Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S . Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol. 2004; 11(5):435-42. DOI: 10.1038/nsmb758. View

12.

Silvas T, Hou S, Myint W, Nalivaika E, Somasundaran M, Kelch B . Substrate sequence selectivity of APOBEC3A implicates intra-DNA interactions. Sci Rep. 2018; 8(1):7511. PMC: 5951847. DOI: 10.1038/s41598-018-25881-z. View

13.

Roberts S, Lawrence M, Klimczak L, Grimm S, Fargo D, Stojanov P . An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013; 45(9):970-6. PMC: 3789062. DOI: 10.1038/ng.2702. View

14.

Sheehy A, Gaddis N, Choi J, Malim M . Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002; 418(6898):646-50. DOI: 10.1038/nature00939. View

15.

Kieffer T, Kwon P, Nettles R, Han Y, Ray S, Siliciano R . G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol. 2005; 79(3):1975-80. PMC: 544145. DOI: 10.1128/JVI.79.3.1975-1980.2005. View

16.

Stopak K, de Noronha C, Yonemoto W, Greene W . HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell. 2003; 12(3):591-601. DOI: 10.1016/s1097-2765(03)00353-8. View

17.

Chelico L, Prochnow C, Erie D, Chen X, Goodman M . Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J Biol Chem. 2010; 285(21):16195-205. PMC: 2871487. DOI: 10.1074/jbc.M110.107987. View

18.

Feng Y, Love R, Ara A, Baig T, Adolph M, Chelico L . Natural Polymorphisms and Oligomerization of Human APOBEC3H Contribute to Single-stranded DNA Scanning Ability. J Biol Chem. 2015; 290(45):27188-27203. PMC: 4646388. DOI: 10.1074/jbc.M115.666065. View

19.

Nair S, Rein A . Assay for Cytidine Deaminase Activity of APOBEC3 Protein. Bio Protoc. 2016; 4(20). PMC: 4972333. DOI: 10.21769/bioprotoc.1266. View

20.

Janahi E, McGarvey M . The inhibition of hepatitis B virus by APOBEC cytidine deaminases. J Viral Hepat. 2013; 20(12):821-8. DOI: 10.1111/jvh.12192. View